Complement and polymorphonuclear leukocyte activation each play a role in determining myocardial ischemia-reperfusion injury

被引:2
作者
Atsuumi, T
Yaoita, H
Shichishima, T
Maehara, K
Fujita, T
Maruyama, Y
机构
[1] Fukushima Med Univ, Dept Internal Med 1, Fukushima 9601295, Japan
[2] Fukushima Med Univ, Dept Biochem 2, Fukushima 9601295, Japan
来源
JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION | 2001年 / 65卷 / 07期
关键词
complement; infarction; polymorphonuclear leukocytes;
D O I
10.1253/jcj.65.659
中图分类号
N09 [自然科学史]; B [哲学、宗教];
学科分类号
01 ; 0101 ; 010108 ; 060207 ; 060305 ; 0712 ;
摘要
Cobra venom factor (CVF) transiently activates polymorphonuclear leukocytes (PMN) by complement activation, followed by rapid complement depletion and gradual reversal of PMN activation. Utilizing these sequential changes caused by CVF, the individual and combined effects of complement and PMNs on myocardial infarct size (IS) were investigated. Rats were treated with CVF, and/or anti-PMNs. Complement was depleted, but circulating PMNs were being activated at 4h after CVF administration, and at 36h after, complement was depleted, but PMNs were in a near basal condition. Under anesthesia, the rats had a 30-min coronary occlusion followed by 6h of reperfusion. The IS was assessed by tetrazolium staining. CVF, as well as anti-PMNs, reduced myeloperoxidase (MPO) activity in the risk area and the reduced MPO resulted in a reduced IS, which was also the effect of anti-PMNs, but complement depletion by CVF, during which circulating PMNs were activated, failed to reduce the IS despite low MPO activity. These results suggest that complement and the condition of PMNs each play a role in determining the IS, and ischemic reperfusion injury might be produced even by relatively low myocardial MPO activity.
引用
收藏
页码:659 / 666
页数:8
相关论文
共 50 条
[11]   Role of complement and perspectives for intervention in ischemia-reperfusion damage [J].
Banz, Yara ;
Rieben, Robert .
ANNALS OF MEDICINE, 2012, 44 (03) :205-217
[12]   Effect of trapidil in myocardial ischemia-reperfusion injury in rabbit [J].
Liu, MingJie ;
Sun, Qi ;
Wang, Qiang ;
Wang, Xiuying ;
Lin, Peng ;
Yang, Ming ;
Yan, Yuanyuan .
INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 (02) :207-210
[13]   Characterization of early myocardial inflammation in ischemia-reperfusion injury [J].
Wu, Qihong ;
Xu, Rong ;
Zhang, Kun ;
Sun, Ran ;
Yang, Mengxi ;
Li, Kuan ;
Liu, Hanrui ;
Xue, Yiyuan ;
Xu, Huayan ;
Guo, Yingkun .
FRONTIERS IN IMMUNOLOGY, 2023, 13
[14]   Long Noncoding RNAs in Myocardial Ischemia-Reperfusion Injury [J].
Zhao, Zhuo ;
Sun, Wei ;
Guo, Ziyuan ;
Liu, Bin ;
Yu, Hongyu ;
Zhang, Jichang .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021
[15]   MYOCARDIAL AND ENDOTHELIAL PROTECTION BY TMS IN ISCHEMIA-REPERFUSION INJURY [J].
MUROHARA, T ;
BUERKE, M ;
MARGIOTTA, J ;
RUAN, FQ ;
IGARASHI, Y ;
HAKOMORI, SI ;
LEFER, AM .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1995, 269 (02) :H504-H514
[16]   Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury [J].
Gorsuch, W. Brian ;
Guikema, Benjamin J. ;
Fritzinger, David C. ;
Vogel, Carl-Wilhelm ;
Stahl, Gregory L. .
MOLECULAR IMMUNOLOGY, 2009, 47 (2-3) :506-510
[17]   Muscone ameliorates myocardial ischemia-reperfusion injury by promoting myocardial glycolysis [J].
Gu, Xin ;
Bao, Neng ;
Zhang, Jing ;
Huang, Guangyi ;
Zhang, Xiaodong ;
Zhang, Zhixuan ;
Du, Yinqiang ;
Meng, Haoyu ;
Liu, Jiabao ;
Wu, Peng ;
Wang, Xiaoyan ;
Wang, Guangyan .
HELIYON, 2023, 9 (11)
[18]   Cardioprotective effects of tilianin in rat myocardial ischemia-reperfusion injury [J].
Guo, Xinhong ;
Cao, Wenjiang ;
Yao, Jiaming ;
Yuan, Yong ;
Hong, Ye ;
Wang, Xinchun ;
Xing, Jianguo .
MOLECULAR MEDICINE REPORTS, 2015, 11 (03) :2227-2233
[19]   Novel roles of κ-opioid receptor in myocardial ischemia-reperfusion injury [J].
Zhang, Wen ;
Zhang, Qi ;
Liu, Yali ;
Pei, Jianming ;
Feng, Na .
PEERJ, 2024, 12
[20]   Kirenol Ameliorates Myocardial Ischemia-Reperfusion Injury by Promoting Mitochondrial Function and Inhibiting Inflammasome Activation [J].
Pan, Lei ;
Fu, Mingqiang ;
Tang, Xiang-lin ;
Ling, Yunlong ;
Su, Yangang ;
Ge, Junbo .
CARDIOVASCULAR DRUGS AND THERAPY, 2024,